Combined Intranasal Insulin/Saxagliptin/Metformin Therapies Ameliorate the Effect of Combined Oral Contraceptive- (COC-) Induced Metabolic Syndrome (MetS) with a Major Target on Glucose Metabolism in Adult Female Wistar Rats - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34938803/
Objective: To evaluate the effect of the chronic use of combined oral contraceptives (COCs: ethinyl estradiol and levonorgestrel) on the indices of metabolic syndrome in adult female Wistar rats and possible therapeutic management. Materials and methods: 64 female Wistar rats received either distilled water, norethindrone (NOR), COC, intranasal insulin (INI), metformin (MET), saxagliptin (SAX), INI+MET, and INI+SAX.
Conclusions: The use of MET and SAX in combination with INI has been shown to reverse some indices of MetS. This study proposes a clinical phase to backup and ascertain these preclinical findings.
• Source: International Journal of Reproductive Medicine
• Conclusions: “The use of MET [metformin] and SAX [saxagliptin] in combination with INI [insulin] has been shown to reverse some indices of MetS [metabolic syndrome]. This study proposes a clinical phase to backup and ascertain these preclinical findings.”
• The researchers assessed the effects of combined oral contraceptives in rats on aspects of metabolic syndrome, as well as the benefits of intranasal insulin, metformin, and saxagliptin in the management of this condition.
• “It is expected that the results from this study shed light on the underlying therapeutic intervention for this disorder occasioned by a chronic administration of COC in adult female albino Wistar rats,” wrote the authors.
• The authors suggested that the status of metabolic syndrome in patients taking combined oral contraceptive be closely monitored, with therapeutic interventions used to decrease the risk of type 2 DM and heart disease. Results of the current study warrant clinical study, according to the authors.